BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Galvão-Coelho NL, Marx W, Gonzalez M, Sinclair J, de Manincor M, Perkins D, Sarris J. Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants. Psychopharmacology (Berl) 2021;238:341-54. [PMID: 33427944 DOI: 10.1007/s00213-020-05719-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 29.0] [Reference Citation Analysis]
Number Citing Articles
1 Shahar O, Botvinnik A, Esh-zuntz N, Brownstien M, Wolf R, Lotan A, Wolf G, Lerer B, Lifschytz T. Role of 5-HT2A, 5-HT2C, 5-HT1A and TAAR1 Receptors in the Head Twitch Response Induced by 5-Hydroxytryptophan and Psilocybin: Translational Implications. IJMS 2022;23:14148. [DOI: 10.3390/ijms232214148] [Reference Citation Analysis]
2 de Meiroz Grilo MLP, Sousa GMD, Mendonça LACD, Lobão-soares B, Sousa MBCD, Palhano-fontes F, Araujo DBD, Perkins D, Hallak JEC, Galvão-coelho NL. Prophylactic action of ayahuasca in a non-human primate model of depressive-like behavior. Front Behav Neurosci 2022;16. [DOI: 10.3389/fnbeh.2022.901425] [Reference Citation Analysis]
3 Vanderzwaag J, Halvorson T, Dolhan K, Šimončičová E, Ben-azu B, Tremblay M. The Missing Piece? A Case for Microglia’s Prominent Role in the Therapeutic Action of Anesthetics, Ketamine, and Psychedelics. Neurochem Res 2022. [DOI: 10.1007/s11064-022-03772-0] [Reference Citation Analysis]
4 Rossi GN, Guerra LTL, Baker GB, Dursun SM, Saiz JCB, Hallak JEC, dos Santos RG. Molecular Pathways of the Therapeutic Effects of Ayahuasca, a Botanical Psychedelic and Potential Rapid-Acting Antidepressant. Biomolecules 2022;12:1618. [DOI: 10.3390/biom12111618] [Reference Citation Analysis]
5 Guglielmo R, Hasler G. The neuroprotective and neuroplastic potential of glutamatergic therapeutic drugs in bipolar disorder. Neuroscience & Biobehavioral Reviews 2022;142:104906. [DOI: 10.1016/j.neubiorev.2022.104906] [Reference Citation Analysis]
6 Ko K, Kopra EI, Cleare AJ, Rucker JJ. TEMPORARY REMOVAL: Psychedelic therapy for depressive symptoms: Asystematic review and meta-analysis. Journal of Affective Disorders 2022. [DOI: 10.1016/j.jad.2022.09.168] [Reference Citation Analysis]
7 Rosenblat JD, Husain MI, Lee Y, McIntyre RS, Mansur RB, Castle D, Offman H, Parikh SV, Frey BN, Schaffer A, Greenwaym KT, Garel N, Beaulieu S, Kennedy SH, Lam RW, Milev R, Ravindran AV, Tourjman V, Ameringen MV, Yatham LN, Taylor V. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder. Can J Psychiatry 2022;:7067437221111371. [PMID: 35975555 DOI: 10.1177/07067437221111371] [Reference Citation Analysis]
8 Schmitz GP, Jain MK, Slocum ST, Roth BL. 5-HT2A SNPs Alter the Pharmacological Signaling of Potentially Therapeutic Psychedelics. ACS Chem Neurosci 2022. [PMID: 35894503 DOI: 10.1021/acschemneuro.1c00815] [Reference Citation Analysis]
9 Shahar O, Botvinnik A, Esh-zuntz N, Brownstien M, Wolf R, Wolf G, Lerer B, Lifschytz T. Role of 5-HT2A, 5-HT2C, 5-HT1A and TAAR1 receptors in the head twitch response induced by 5-hydroxytryptophan and psilocybin: Translational implications.. [DOI: 10.1101/2022.07.22.501026] [Reference Citation Analysis]
10 Daldegan-Bueno D, Révész D, Morais PR, Barbosa PCR, Maia LO. Psychosocial and Drug Use Assessment of Regular vs. Non-Regular Ayahuasca Users in a Brazilian Sample: a Web-Based Survey. Subst Use Misuse 2022;57:1072-81. [PMID: 35466853 DOI: 10.1080/10826084.2022.2063896] [Reference Citation Analysis]
11 Henner RL, Keshavan MS, Hill KP. Review of potential psychedelic treatments for PTSD. Journal of the Neurological Sciences 2022. [DOI: 10.1016/j.jns.2022.120302] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Orłowski P, Ruban A, Szczypiński J, Hobot J, Bielecki M, Bola M. Naturalistic use of psychedelics is related to emotional reactivity and self-consciousness: The mediating role of ego-dissolution and mystical experiences. J Psychopharmacol 2022;:2698811221089034. [PMID: 35475373 DOI: 10.1177/02698811221089034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Rossi GN, Hallak JEC, Bouso Saiz JC, dos Santos RG. Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges. Expert Opinion on Drug Safety. [DOI: 10.1080/14740338.2022.2066650] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
14 van den Berg M, Magaraggia I, Schreiber R, Hillhouse TM, Porter JH. How to account for hallucinations in the interpretation of the antidepressant effects of psychedelics: a translational framework. Psychopharmacology (Berl) 2022. [PMID: 35348806 DOI: 10.1007/s00213-022-06106-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Hendricks PS, Copes H, Family N, Williams LT, Luke D, Raz S. Perceptions of safety, subjective effects, and beliefs about the clinical utility of lysergic acid diethylamide in healthy participants within a novel intervention paradigm: Qualitative results from a proof-of-concept study. J Psychopharmacol 2022;36:337-47. [DOI: 10.1177/02698811211055855] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Sarris J. Disruptive innovation in psychiatry. Ann N Y Acad Sci 2022. [PMID: 35233789 DOI: 10.1111/nyas.14764] [Reference Citation Analysis]
17 Yu C, Liang C, Yang F, Tu Y, Hsu C, Carvalho AF, Stubbs B, Thompson T, Tsai C, Yeh T, Yang S, Shin JI, Chu C, Tseng P, Su K. Trajectory of Antidepressant Effects after Single- or Two-Dose Administration of Psilocybin: A Systematic Review and Multivariate Meta-Analysis. JCM 2022;11:938. [DOI: 10.3390/jcm11040938] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Kelly JR, Gillan CM, Prenderville J, Kelly C, Harkin A, Clarke G, O'Keane V. Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective. Front Psychiatry 2021;12:800072. [PMID: 34975593 DOI: 10.3389/fpsyt.2021.800072] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
19 Khan AJ, Bradley E, O’donovan A, Woolley J. Psilocybin for Trauma-Related Disorders. Disruptive Psychopharmacology 2022. [DOI: 10.1007/7854_2022_366] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Sarris J, Pinzon Rubiano D, Day K, Galvão-Coelho NL, Perkins D. Psychedelic medicines for mood disorders: current evidence and clinical considerations. Curr Opin Psychiatry 2022;35:22-9. [PMID: 34855694 DOI: 10.1097/YCO.0000000000000759] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
21 Reif A, Baune BT, Deckert J, Juckel G, Kittel-Schneider S, Kircher T, Kornhuber J, Rupprecht R, Bauer M. Rationale, Mission and Vision for a National Centre of Affective Disorders in Germany. Pharmacopsychiatry 2021. [PMID: 34921380 DOI: 10.1055/a-1697-5854] [Reference Citation Analysis]
22 Schmitz GP, Jain MK, Slocum ST, Roth BL. Pharmacologic analysis of non-synonymous coding 5-HT2A SNPs reveals alterations psychedelic drug potencies and efficacies.. [DOI: 10.1101/2021.12.09.472000] [Reference Citation Analysis]
23 Gard DE, Pleet MM, Bradley ER, Penn AD, Gallenstein ML, Riley LS, Dellacrosse M, Garfinkle EM, Michalak EE, Woolley JD. Evaluating the risk of psilocybin for the treatment of bipolar depression: A review of the research literature and published case studies. Journal of Affective Disorders Reports 2021;6:100240. [DOI: 10.1016/j.jadr.2021.100240] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Gass P, Vasilescu AN, Inta D. [Rapid-acting antidepressants-neurobiological mechanisms of action]. Nervenarzt 2021. [PMID: 34766186 DOI: 10.1007/s00115-021-01225-7] [Reference Citation Analysis]
25 Vargas MV, Meyer R, Avanes AA, Rus M, Olson DE. Psychedelics and Other Psychoplastogens for Treating Mental Illness. Front Psychiatry 2021;12:727117. [PMID: 34671279 DOI: 10.3389/fpsyt.2021.727117] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 12.0] [Reference Citation Analysis]
26 Aleksandrova LR, Phillips AG. Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics. Trends Pharmacol Sci 2021;42:929-42. [PMID: 34565579 DOI: 10.1016/j.tips.2021.08.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 18.0] [Reference Citation Analysis]
27 Zeiss R, Gahr M, Graf H. Rediscovering Psilocybin as an Antidepressive Treatment Strategy. Pharmaceuticals (Basel) 2021;14:985. [PMID: 34681209 DOI: 10.3390/ph14100985] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Chambers RA, Toombs C. Deep Network Pharmacology: Targeting Glutamate Systems as Integrative Treatments for Jump-Starting Neural Networks and Recovery Trajectories. J Psychiatr Brain Sci 2021;6:e210008. [PMID: 34549091 DOI: 10.20900/jpbs.20210008] [Reference Citation Analysis]
29 Psiuk D, Nowak E, Cholewa K, Łopuszańska U, Samardakiewicz M. The Potential Role of Serotonergic Hallucinogens in Depression Treatment. Life (Basel) 2021;11:765. [PMID: 34440508 DOI: 10.3390/life11080765] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
30 de Sousa MBC, de Meiroz Grilo MLP, Galvão-Coelho NL. Natural and Experimental Evidence Drives Marmosets for Research on Psychiatric Disorders Related to Stress. Front Behav Neurosci 2021;15:674256. [PMID: 34177478 DOI: 10.3389/fnbeh.2021.674256] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Rush B, Marcus O, García S, Loizaga-Velder A, Loewinger G, Spitalier A, Mendive F. Protocol for Outcome Evaluation of Ayahuasca-Assisted Addiction Treatment: The Case of Takiwasi Center. Front Pharmacol 2021;12:659644. [PMID: 34093190 DOI: 10.3389/fphar.2021.659644] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
32 Gard DE, Pleet MM, Bradley ER, Penn A, Gallenstein ML, Riley LS, Dellacrosse M, Garfinkle E, Michalak EE, Woolley JD. Evaluating the Risk of Psilocybin for the Treatment of Bipolar Depression: A Review of the Research Literature and Published Case Studies.. [DOI: 10.1101/2021.04.02.21254838] [Reference Citation Analysis]
33 Perkins D, Sarris J, Rossell S, Bonomo Y, Forbes D, Davey C, Hoyer D, Loo C, Murray G, Hood S, Schubert V, Galvão-Coelho NL, O'Donnell M, Carter O, Liknaitzky P, Williams M, Siskind D, Penington D, Berk M, Castle D. Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm. Aust N Z J Psychiatry 2021;:4867421998785. [PMID: 33745287 DOI: 10.1177/0004867421998785] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]